Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Liabilities and Shareholders Equity of $3.0 billion for Q2 2026, little changed year-over-year from $3.0 billion in Q2 2025, and down 13.2% quarter-over-quarter from $3.4 billion in Q1 2026.
Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $3.0 billion for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity changed 0.31% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $13.0 billion (up 9.41% YoY), while the FY2025 annual figure was $3.5 billion, up 17.32% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $3.0 billion, down from $3.4 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $3.5 billion in Q4 2025, with the low at $2.4 billion in Q3 2022.
- The 5-year median for Liabilities and Shareholders Equity is $3.0 billion (2023), against an average of $2.9 billion.
- The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity declined 9.42% in 2024, then gained 22.65% in 2026.
- Ionis Pharmaceuticals' Liabilities and Shareholders Equity stood at $2.5 billion in 2022, then rose by 18.0% to $3.0 billion in 2023, then advanced by 0.45% to $3.0 billion in 2024, then increased by 17.32% to $3.5 billion in 2025, then slipped by 15.02% to $3.0 billion in 2026.
- Business Quant data shows IONS's Liabilities and Shareholders Equity at $3.0 billion in Q2 2026, $3.4 billion in Q1 2026, and $3.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 2.99 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.99 Bn |
| Mar 31, 2026 | 3.45 Bn |
| Dec 31, 2025 | 3.52 Bn |
| Sep 30, 2025 | 3.03 Bn |
| Jun 30, 2025 | 2.99 Bn |
| Mar 31, 2025 | 2.81 Bn |
| Dec 31, 2024 | 3.00 Bn |
| Sep 30, 2024 | 3.08 Bn |
| Jun 30, 2024 | 2.69 Bn |
| Mar 31, 2024 | 2.76 Bn |
| Dec 31, 2023 | 2.99 Bn |
| Sep 30, 2023 | 2.93 Bn |
| Jun 30, 2023 | 2.97 Bn |
| Mar 31, 2023 | 2.89 Bn |
| Dec 31, 2022 | 2.53 Bn |
| Sep 30, 2022 | 2.42 Bn |
| Jun 30, 2022 | 2.46 Bn |
| Mar 31, 2022 | 2.52 Bn |
| Dec 31, 2021 | 2.61 Bn |
| Sep 30, 2021 | 2.41 Bn |